App-Quantinova.ai

Seronegative arthritis in the context of CHIP: is this a new entity that needs further investigation?

Sarah Mohamed - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Seronegative arthritis

Hydroxychloroquine

Hydroxychloroquine synergizes with anti-PD-1 immune checkpoint blockade in squamous carcinoma of the head and neck

Avani Vyas - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Hydroxychloroquine

Exploratory platform trial to evaluate immunotherapy combinations with chemotherapy for the treatment of patients with previously untreated metastatic pancreatic adenocarcinoma (REVOLUTION)

Jaclyn Lyman - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic pancreatic adenocarcinoma

Hydroxychloroquine

Hydroxychloroquine and Azithromycin Usage in African American Patients With Coronavirus Disease 2019 (COVID-19) and Their Effects on QT Interval

Mohammed Al-Sadawi - Transcatheter Cardiovascular Therapeutics (TCT) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

Hydroxychloroquine

SYSTEMS BIOLOGY-BASED THERAPEUTIC PREDICTIONS WITH GBMSYGNAL AND CLINICAL CORRELATES IN THE REAL-WORLD LONGITUDINAL OUTCOMES REGISTRY XCELSIOR

Timothy Stuhlmiller - Society for Neuro-Oncology (SNO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

Hydroxychloroquine

Antiphospholipid Antibody Syndrome and Protein S Deficiency: A Successful Pregnancy Outcome

Umme Ruman - International Federation of Gynecology and Obstetrics (FIGO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Antiphospholipid syndrome

Hydroxychloroquine

Pregnancy with Lupus Nephritis: 2 case reports

Sadia Parween - International Federation of Gynecology and Obstetrics (FIGO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Lupus nephritis

Hydroxychloroquine

Clinical investigation of JAK inhibitor Tofacitinib in scarring alopecias

L. Bordone - International Investigative Dermatology/Society for Investigative Dermatology (IID/SID) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Fibrosing alopecia

Hydroxychloroquine

Increased population of myeloid dendritic cells and upregulated gene expression of TNF α is associated with poor response to hydroxychloroquine In cutaneous lupus

M. Zeidi - International Investigative Dermatology/Society for Investigative Dermatology (IID/SID) , 2021

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Cutaneous lupus erythematosus

Hydroxychloroquine

The quinacrine experience in a population of cutaneous lupus erythematosus and dermatomyositis patients

L. Mittal - International Investigative Dermatology/Society for Investigative Dermatology (IID/SID) , 2021

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Cutaneous lupus erythematosus

Hydroxychloroquine

Cutaneous lupus erythematosus treated with energy based devices

S. Song - International Investigative Dermatology/Society for Investigative Dermatology (IID/SID) , 2023

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Cutaneous lupus erythematosus

Hydroxychloroquine

Hydroxychloroquine restores burn damage through the Wnt/β-catenin pathway

S. Tang - International Investigative Dermatology/Society for Investigative Dermatology (IID/SID) , 2023

Therapeutic Area

Disease

Drug/Treatment

N/A

Hydroxychloroquine

Adverse events associated with hydroxychloroquine use in cicatricial alopecia patients

M. Collins - International Investigative Dermatology/Society for Investigative Dermatology (IID/SID) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Left ventricular hypertrophy

Hydroxychloroquine

Unsupervised learning reveals different degrees of heterogeneity as well as cell involvement in cutaneous lupus erythematous antimalarial treatment response subgroups

F. Chin - International Investigative Dermatology/Society for Investigative Dermatology (IID/SID) , 2022

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Cutaneous lupus erythematosus

Hydroxychloroquine

Efficacy Of Hydroxychloroquine in Refractory Chronic Idiopathic Urticaria (RCIU)

Najeeb Khan - American Academy of Allergy, Asthma, and Immunology (AAAAI) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Hydroxychloroquine

Atypical diabetes with spontaneous remission associated with systemic lupus erythematosus in an adolescent girl with African ancestry

Fanny Luterbacher - European Society for Paediatric Endocrinology (ESPE) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Lupus

Hydroxychloroquine

HYDROXYCHLOROQUINE PREVENTS THE DISEASE PROGRESSION IN THE MURINE IGA NEPHROPATHY MODEL VIA INHIBITING TLR9/TLR7 SIGNALS AND RELATED CYTOKINES

M. Lee - International Society of Nephrology (ISN) , 2022

Therapeutic Area

Disease

Drug/Treatment

Nephrology

IgA nephropathy

Hydroxychloroquine

TWIN WITH LUPUS NEPHRITIS: THE TALE OF NEPHRECTOMY, IVF TWIN PREGNANCY LOSS AND MORE

N. BASHIR - International Society of Nephrology (ISN) , 2022

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Lupus

Hydroxychloroquine

COULD DEXAMETHASONE ADMINISTRATION BE LIFESAVING IN PATIENTS ON IMMUNOSUPPRESSION INFECTED BY COVID 19?

A.F. MEGAHED - International Society of Nephrology (ISN) , 2022

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Renal insufficiency

Hydroxychloroquine

Cardiac Safety of Imatinib for the Treatment of Covid-19: Results from a Randomized, Double Blind, Placebo-Controlled Trial

E. Duijvelaar - American Thoracic Society (ATS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Diabetes

Hydroxychloroquine

Filters

1151 Abstracts